cyrilzakka/clinical-trials huggingface dataset:
Evaluation of the Effectiveness of a Continuing Education Program in Community Pharmacies

Preventable failures in the drug chain are related to Drugs Problems Related Use and are associated with medication errors (prescription, dispensing, administration or use by the patient or caregiver), including failures In the Medication Supply System (availability and quality).

The controlled drugs are those that contain substances regulated by international conventions on drug control. They are important in various fields of medicine, such as pain management, obstetric emergencies, mental disorders such as the treatment of substance dependence, psychiatry and neurology. It has been defined as abuse of drugs the improper use of these for non-medical purposes, and associated with the use without medical prescription, which can produce addiction or psychic or physical dependence.

Experimental study with random assignment of the staff pharmacist of Pharmacies. The staff pharmacists admitted will be followed for 12 months (1 year). The study will make it possible to determine the effect of the continuing education program accompanied by Information and Communication Technologies (ICT).

Eligibility Criteria:
Inclusion Criteria:

1. Pharmacy staff working in Pharmacy or Drugstore, located geographically in the city of Medellín and in the Metropolitan Area
2. That the owner works in the establishment

Inclusion Exclusion:

1. Pharmacy staff who do not agree to participate in the study
Knowledge Beliefs and Expectations of Chronic Musculoskeletal Patients About Their Physiotherapy Program

The purpose of this study is to investigate the knowledge, beliefs and expectations of patients with chronic musculoskeletal pain about their physiotherapy program and the relationship that they built with physiotherapists.

The main questions of this study are:

Have patients with chronic pain educated in pain? To what extent physiotherapists use appropriate communication skills and show empathy? What expectations do the patients have of their rehabilitation program?

Eligibility Criteria:
Inclusion Criteria:

* Patients with chronic musculoskeletal pain more than 3 months and intensity more than 3/10 VAS.
* Greek speaking patients
* patients who are following or followed a physiotherapy treatment for their pain

Exclusion Criteria:

* None
Stress and Coping, Resilience, and Compassion Fatigue of Front-line Nurses During COVID-19 Pandemic

This is a cross-sectional research. The investigators plan to recruit about 250 front-line nurses who provided direct care to COVID-19 confirmed cases in a medical center in Taiwan. Online querstionnaires are used to collect the data. The relationship between variables such as stressors related to COVID-19, coping status, resilience, and compassion fatigue of participants will be analysis to provide the direction of nurses' mental health-related interventions.

This project aims to identify the prevalence of compassion fatigue and the coping strategies for the nurses who work on the frontline of healthcare and are responsible for caring for patients with COVID-19 in Taiwan. The investigators planed to carry a cross-sectional study by a reliable and valid online questionnaire to explore the stressors related to COVID-19, coping status, resilience, and compassion fatigue of nurses who had the experience of caring for the COVID-19 confirmed cases in a medical center during the community outbreak in Taiwan from May 2021. Online questionnaires are used to collect the data. About two hundred and fifty nurses will be recruited, and the data will be analyzed by descriptive statistics, correlation statistics and Hayes's PROCESS model 6. It is expected that the research results can understand the current status and relationship of compassion fatigue, resilience and the adaptability of clinical nurses who are caring for the COVID-19 confirmed cases. The results can be contributed to develop the direction of nurses' mental health-related interventions during pandemic of emerging contagious disease.

Eligibility Criteria:
Inclusion Criteria:

* Above/include 20-year-old.
* Those who can operate mobile communication software or computers and can fill in online questionnaires.
* Clinical nurses who had provided nursing care for COVID-19 confirmed cases from May 2021.

Exclusion Criteria:

* Those who did not provide nursing care for COVID-19 confirmed cases.
iNod™ Ultrasound-Guided Needle Biopsy System Study

The purpose of this study is to collect information on the iNod™ System's safety and ability to see the iNod™ biopsy needle in real-time in endobronchial lesions, peripheral lung nodules, or lung masses.

This post-market study intends to further demonstrate the ability and safety of the iNod™ Ultrasound Guidance System and iNod™ Ultrasound Biopsy needle to perform transbronchial needle biopsy of endobronchial lesions, peripheral lung nodules, or lung masses under real-time ultrasound visualization. This is a prospective, multi-center case series of standard of care peripheral lung nodule biopsy procedures with up to 115 subjects at up to 10 centers.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 years or older.
2. Subject willing and able to comply with study procedures and provide written informed consent to participate in study.
3. Subject with a predominantly solid, peripheral lung lesion, 1 cm to 5 cm in diameter measured along its longest cross sectional diameter on axial CT imaging (obtained within 4 weeks per standard of practice) with the intention to undergo a clinically indicated bronchoscopic evaluation under routine clinical care. If the lesion is partially solid (i.e. there is a ground glass component) then the solid portion must make up at least 80% of the lesion.

   a. "Peripheral" lesion in this study will be pragmatically defined as any lesion in the lung parenchyma that the clinician feels cannot be accessed successfully using the convex probe endobronchial ultrasound bronchoscope.
4. Subject for whom the decision to pursue biopsy has been made by the treating physician and agreed upon by the subject.

Exclusion Criteria:

1. Subjects with pure ground glass opacity or a subsolid target lesion, and/or a ground glass opacity for which less than 80% of the lesion is solid identified by Chest CT.
2. Subjects who have medical contraindication to undergo conventional flexible or robotic bronchoscopy and standard of care Radial EBUS-guided cytological assessment evaluations, as determined by the investigator.
3. Subjects with known coagulopathy.
4. Subjects who are pregnant or nursing mothers.
5. Subjects who are currently enrolled in another investigational study that would directly interfere with the current study, without prior written approval from the sponsor.
6. Use of intraprocedural Cone Beam CT, Fixed CT or Augmented fluoroscopy
5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome

The purpose of this study is to examine the feasibility and efficacy of using the demethylating agent 5-Azacytidine prior to allogeneic stem cell transplantation in patients with high risk myelodysplastic syndrome (MDS).

The study drug, 5-azacytidine, is given daily intravenously for 7 days. After every 2 cycles study participants will have a bone marrow test to evaluate the effect of the 5-azacytidine on the Myelodysplastic Syndrome (MDS). Participants continue to get cycles of 5-Azacytidine until 2 bone marrow tests show the MDS has stopped responding to the treatment. At that time they will undergo a transplant if a donor is available.

Eligibility Criteria:
Inclusion Criteria:

* Patients fulfilling the following criteria will be eligible for study entry:

  1. Diagnosis of MDS according to WHO criteria
  2. Intermediate-2 or high risk by IPSS score
  3. Clinically able to receive 5-Azacytidine
  4. Serum bilirubin levels \</=1.5 times the upper limit of the normal range for the laboratory (ULN). Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis
  5. Serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic-pyruvic transaminase (SGPT) levels \</=2 x ULN
  6. Serum creatinine levels \</=1.5 x ULN
  7. Negative serum pregnancy test prior to 5-Azacytidine treatment for women of childbearing potential
  8. Women and men of childbearing potential agree to use contraception while receiving treatment with 5-Azacytidine
  9. Potentially eligible for allogeneic transplantation
  10. No prior allogeneic transplant
  11. Age 18 to 70, inclusive.

Exclusion Criteria:

1. Known or suspected hypersensitivity to 5-azacytidine or mannitol
2. Patients previously treated with 5-azacytidine or deoxyazacytidine
3. Pregnant or breast feeding
4. Patients with advanced malignant hepatic tumors
Evaluation of the Novel Use of Gamification With Alternative Goal-setting Experiences

To use a randomized controlled trial to test the effectiveness of four goal-setting strategies within a gamification intervention to increase physical activity among adults at elevated risk for ASCVD.

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in the United States. While increased physical activity can reduce this risk, less than half of adults in the United States meet the minimum recommendation guidelines for physical activity. Gamification, or the application of game design elements to non-game settings, has demonstrated promise in increasing physical activity when designed using insights from behavioral economics. However, the best way to design goal-setting within these interventions has not been well-examined. In this randomized controlled trial, the investigators will evaluate the effectiveness of four different goal-setting strategies within a gamification intervention to increase physical activity among adults with elevated risk for ASCVD. The trial will include a 2-week run-in period to estimate a baseline, followed by an 8-week introductory phase, an 8-week maintenance phase, and then after the intervention is completed an 8-week follow-up period.

Eligibility Criteria:
Inclusion Criteria:

* Age 18 years or older;
* ability to read and provide informed consent to participate in the study;
* diagnosis of clinical ASCVD or a 10-year ASCVD risk score ≥ 7.5% calculated according to the 2013 ACC/AHA guidelines;
* Smartphone or tablet compatible with application for the wearable activity tracking device.

Exclusion Criteria:

* Conditions that would make participation infeasible such as inability to provide informed consent, illiteracy or inability to speak, read, and write English;
* conditions that would make participation unsafe such as pregnancy or being told by a physician not to exercise;
* already enrolled in another study targeting physical activity;
* any other medical conditions or reasons he or she is unable to participate in a physical activity study for 24 weeks;
* baseline step count of 10,000 steps or greater.
AMBULATE VASCADE MVP Same Day Discharge Retrospective Registry

A multi-center, retrospective, single arm post market registry to evaluate procedural outcomes data using the Cardiva VASCADE MVP Venous Vascular Closure System (VVCS) for the management of the femoral venotomy after catheter-based atrial fibrillation interventions with or without another arrythmia performed via 6-12F procedural sheaths with single or multiple access sites per limb for patients who are discharged the same day.


Eligibility Criteria:
Inclusion Criteria:

1. ≥18 years of age;
2. Underwent catheter-based ablation for atrial fibrillation with or without another arrythmia.
3. VASCADE MVP was the only closure device utilized.
4. Were discharged the same calendar day as the index procedure.
5. Completed a SOC follow-up \> 7 days post-procedure.

Exclusion Criteria:

1. Any additional procedure(s) involving femoral arterial or venous access in either limb within the SOC follow up period as defined by each site (minimum 7 days post-procedure)
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection

This study aims to evaluate whether an investigational monoclonal antibody, CT-011, is safe to give and if it helps patients with hepatitis C virus (HCV). Monoclonal antibodies are a type of drug that is typically given by infusion into a vein (intravenously). Results of this trial will help doctors obtain additional information with regard to the safety and efficacy of CT-011 as a potential treatment for HCV.


Eligibility Criteria:
Inclusion Criteria:

1. Patient is between 18 and 60 years of age, both genders.
2. Biopsy proven infection with Hepatitis C genotype 1.
3. Positive for anti-HCV.
4. Chronically infected for at least 3 months from diagnosis.
5. ECOG performance status ≤ 1.
6. Previous therapy with interferon +/- Ribavirin or Peginterferon +/- Ribavirin or ineligibility for this type of therapy or for liver transplantation.

Exclusion Criteria:

1. Patients who received any type of anti viral treatment during the 3 months prior to enrollment.
2. Any history or active malignancy.
3. History of major organ transplantation with an existing functional graft.
4. Patients who received any systemic concurrent therapy within the last 4 weeks.
5. Patients progressing to acute liver failure (ALF).
Glycemic and Insulinemic Responses of Low-Carbohydrate Snack Foods

The aim of this study is develop recipes containing CHO less than ICR, prepare new snacks alternatives that could be consumed without need for additional insulin doses, and evaluate the glycemic and insulinemic responses of these recipes. A randomized crossover trial will include 15 healthy adults aged 19-30 years. All participants will consume 3 test foods and reference food (glucose solution, 2 times) in a random order. Blood samples will be collected at time points 0,15, 30, 45, 60, 90 and 120 min. Glucose and insulin analyzes will be performed from blood samples. The results of these time points will be marked on the chart and the incremental area under the curve (iAUC) will be calculated for both glucose and insulin.


Eligibility Criteria:
Inclusion Criteria:

* Healthy volunteer
* Normal body weight (18.5-25 kg / m2 BMI)
* 19-30 years old

Exclusion Criteria:

* use of tobacco,
* weight change of \>5 kg in the last 3 months
* the presence of any chronic disease or lactose intolerance,
* regular medicine use,
* pregnancy or lactation,
* performing competitive sports or endurance sports,
* fasting plasma glucose concentration \>100 mg / dL,
* the presence of eating disorder,
* sensitivity or allergies to any food that used in the study
Bilateral, Masked Comparison of PEG-400 Based Artificial Tear and Systane for the Treatment of Dry Eye Signs, Symptoms and Visual Quality

To evaluate and compare the effects of PEG-400 based artificial tear and Systane tears in mild-moderate dry eye patients. TBUT, Visual impact and subjective evaluations will be assessed in this month long trial.


Eligibility Criteria:
Inclusion Criteria:

* Patient reported dry eye symptoms (episodic, annoying, activity limiting), SES OD.
* Physician assessment of mild-moderate dry eye
* Patient willing to instill drops QID and complete entire length of protocol.
* TBUT \< 10 seconds
* BCVA of 20/30 or better

Exclusion Criteria:

* Current topical cyclosporine use (Restasis)
* Current Systane use
* Refractive surgery within the last 6 months
* Oral or topical corticosteroid use
* Severe dry eye patients by physician assessment
* current active Blepharitis
* Oral Doxycyclines use
* Oral Antihistamine use
Predictive Role of Glucose/Potassium Ratio on Mortality in Major Burns.

The aim of this observational study is to investigate the role of the glucose-potassium ratio in predicting mortality in patients with major burn trauma.

The main question it aims to answer is: Can the glucose-potassium ratio predict mortality in major burn patients? The glucose-to-potassium ratios of major burn patients at the time of initial hospitalization will be determined, and their relationship with mortality will be analyzed.

Major burns, especially electrical burns, facial burns, inhalation burns, burns with large burn surface areas, and deep burns, have a high mortality risk. Early detection of this risk may be critical to reducing mortality rates. For this reason, trauma centers are working on rapid and effective prognostic markers. In trauma and stress situations, glucose levels rise while potassium levels fall due to increased catecholamines. The literature reports that hyperglycemia, also known as the glucose-potassium ratio, can rapidly and effectively predict morbidity and mortality in patients suffering from subarachnoid hemorrhage, pulmonary embolism, traumatic brain injury, or blunt abdominal trauma. Many publications show that increased glucose is associated with mortality and morbidity in critical illnesses and trauma. The isolated glucose-potassium ratio has a higher predictive ability for mortality and morbidity compared to glucose and potassium levels. In this study, investigators aimed to examine the prognostic value of the glucose-to-potassium ratio in participants with major burn trauma.

Eligibility Criteria:
Inclusion Criteria:

* All burns \>40% of total body surface area (2nd degree or deeper)
* Burns with inhalation injury
* Burns \>20% of total body surface area 3nd degree or deeper

Exclusion Criteria:

* First degree burns
* Patients have more than 24 hours since the onset of burn trauma
* Patients with diabetes mellitus
* Patients with chronic renal failure
* Patients taking potassium-modifying medication
* Patients with missing data
Clinicopathological Features of Renal Cell Carcinoma in Young Patients

Analysis of Clinicopathologic Characters of Renal Cell Carcinoma in Young Patients and their influence on the survival outcomes

Worldwide, RCC accounts for 2-3% of All adult malignancies and the 8th most commonly diagnosed primary cancer among all adults.

Representing 3rd place among urinary system tumors. Most of RCC occurs in old age while about 7% occurs in younger adults below 40 years.

Recently the published data about the tumor Clinco-pathological features, treatment response and outcomes were different in young adults than older patients, where some data showed favorable features and survivals, while other showed negative ones.

Eligibility Criteria:
Inclusion Criteria:

* Age \< 40 years

  * Patients proven to have RCC
  * Patients eligible to receive treatment

Exclusion Criteria:

* Second malignancy.
Mucociliary Clearance, Airway Inflammation and Nasal Symptoms in Urban Motorcycle-drivers

Professionals working in polluted areas may present increased airways symptoms and dysfunction. Rhinopharyngeal retrograde clearance (RRC) has been used to improve mucus clearance in infants with bronchitis and bronchiolitis. Flushing the nasal cavity with saline (S) has been used to reduce nasal inflammation in rhinitis and sinupathies. The aim of this study was to assess the effects of RRC and RRC plus S (RRC+S) on the airways in professional motorcyclists. Twenty-four male motorcyclists (mean age 36 years) were randomly assigned to RRC or RRC+S. Subjects were assessed at baseline and 15 days after interventions for airways assessments by saccharin test, mucus contact angle, cellularity in nasal lavage and airways symptoms with the use of SNOT-20 questionnaire. Data were analyzed by nonparametric ANOVA for repeated measures with Bonferroni´s correction. A passive nitrogen dioxide monitoring system was used to assess the mean personal air pollution exposure along the study period (NO2). The association between NO2 and the airways outcomes was analyzed by Spearman correlation test. At baseline, the two groups were similar in clinical, demographics and working aspects. From them, 100% had airways symptoms complaints and 33% had nasal MCC impairment. After treatments, both groups presented improvements in airways symptoms and nasal MCC. However, increased number of macrophages and ciliated cells were observed in nasal lavage of both groups. No associations between nitrogen dioxide and the outcome variables were detected. Rhinopharyngeal retrograde clearance seems to be useful in the clinical management of the upper airways symptoms and dysfunction in adults.

The nonsmokers subjects aged 18 years to 45 years were enrolled in this study after agreement with the written informed consent. Subjects were randomly assigned to 15-days of one of the following interventions: RRC and RRC+S. Non pharmacological respiratory approaches may be useful in the management of the respiratory symptoms and dysfunctions air pollution-related. The purpose of this study was to determine whether saline instillation and/or retrograde rhinopharyngeal retrograde clearance are effective in the treatment of upper airways dysfunction through nasal mucociliary clearance, mucus properties, pH, cellularity and cytokines in nasal lavage and pH in exhaled breath condensate, as well as the airways symptoms (cough, wheeze, runny nose, hoarseness, among others) in motorcyclists due to urban air pollution.

Eligibility Criteria:
Inclusion Criteria:

* Professional motorcyclists aged 18 years to 45 years
* Agreement with the written informed consent

Exclusion Criteria:

* inability to understand and to follow commands,
* previous nasal surgery,
* respiratory infection in the previous 30 days
A Pilot Study to Assess the Effectiveness and Safety of Belotero Balance® Injection for Volume Augmentation of the Infraorbital Hollow

The pilot study aims to define safety, effectiveness, and patient-reported outcomes for Belotero Balance® use in the infraorbital hollows.


Eligibility Criteria:
Inclusion Criteria:

* Has right and left infraorbital hollow (IOH) volume deficit with a rating of 2 or 3 (moderate or severe) on the MIHAS.
* Has the same MIHAS score on both IOHs (i.e., IOHs are symmetrical).
* Is at least 22 years of age.

Exclusion Criteria:

* Ever been treated with fat injections or permanent and/or semi-permanent dermal fillers in the midfacial region.
* Received lower eyelid and/or malar region treatments with any absorbable or temporary fillers such as porcine-based collagen fillers, hyaluronic acid (HA) products, RADIESSE®, poly L-lactic acid (PLLA) or received mesotherapy treatment to the area within the past 24 months or plans to receive such treatments during participation in the study.
Treatment of Osteonecrosis of the Femoral Head by Bone Marrow Transplantation

Aseptic non traumatic osteonecrosis (ON) is a painful disorder of the hip which often leads, in its final stage, to femoral head collapse and subsequent total hip replacement. Core decompression of the hip is the most widespread procedure used to treat early stage ON of the femoral head. Notwithstanding the fact that this procedure has been employed for more than three decades (2), its efficacy remains controversial (3;4). Recently, one suggested that ON might be a disease of bone cells and/or of mesenchymal cells. The levels of activity and the number of mesenchymal stem cells in both the hematopoietic and in the stromal compartments of the bone marrow have been shown to be depressed in patients with ON of the femoral head (9). The investigators have showed previously that the capacity of osteoblastic cells to replicate was decreased in the proximal femur of patients with ON of the femoral head (10). This finding raised the possibility that bone marrow containing stromal cells which have many of the characteristics of stem cell for mesenchymal tissues including bone could be implanted into the necrotic lesion of the femoral head.


Eligibility Criteria:
Inclusion Criteria:

* ARCO stage 1 or 2 osteonecrosis of the femoral head

Exclusion Criteria:

* The investigators excluded patients with evidence of a malignant disorder during the past five years.